REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug
Replimune Group Inc (REPL) shares fell 38% on Tuesday after the FDA released documents ahead of an advisory committee meeting on RP1 plus nivolumab for advanced melanoma. The FDA previously issued complete response letters in July 2025 and April 2026, citing the single-arm IGNYTE trial as not adequate and well controlled. An FDA decision is due Aug 2; Wedbush is Neutral ($9) and BMO Outperform ($16).
How this was made
The 30-second read
Why it matters
The FDA documents released ahead of the advisory committee repeat the central issue: the resubmission still does not provide an adequate, well-controlled investigation demonstrating substantial evidence of effectiveness. This directly pressures approval odds and explains the sharp selloff.
Market read
Company-specific regulatory documentation increases uncertainty into the advisory committee and can drive volatility through the Aug 2 decision deadline.
What to watch
The article emphasizes FDA objections but also notes a response advantage versus historical monotherapy outcomes; traders may be underweighting how panelists interpret evaluability and clinical meaningfulness.
Background
Replimune is seeking accelerated approval for RP1 plus nivolumab in advanced melanoma after progression on anti-PD-1 therapy, with two prior complete response letters.
Ticker impact
FDA released documents reiterating that Replimune’s RP1 resubmission still lacks an adequate, well-controlled study for accelerated approval.
Bias to further downside or high volatility ahead of the panel, with relief possible only if the committee finds efficacy evaluable.
The article ties the selloff to newly released FDA documents and highlights repeated core objections about study design and component contribution, which typically pressures approval odds.
Market effects
Reinforces FDA scrutiny for accelerated approvals based on single-arm oncology trials and component attribution in combination regimens.
Limited broader regional impact; primarily affects US biotech sentiment around FDA advisory outcomes.
Moderate global relevance for oncology accelerated-approval expectations, but the catalyst is company-specific.
Counterpoint
A committee vote could still be favorable if panelists view the RP1 plus nivolumab signal as clinically meaningful despite FDA’s concerns, creating a sharp relief rally.
Key entities
- companyReplimune Group Inc
Subject of the article, REPL, seeking accelerated approval for RP1 plus nivolumab.
- regulatorU.S. Food and Drug Administration
Released documents reiterating the application’s lack of an adequate, well-controlled study.
- eventAdvisory committee meeting
Scheduled for July 30, with documents released earlier on Tuesday ahead of the meeting.
